{
    "clinical_study": {
        "@rank": "18524", 
        "brief_summary": {
            "textblock": "To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected\n      patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses."
        }, 
        "brief_title": "A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cohorts of 16 patients receive 1 of 2 doses of Ro 31-8959 for 20 weeks. Administration of\n      the higher dose will proceed only after 2-week safety data for the first eight patients on\n      the lower dose has been reviewed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 count 200 - 500 cells/mm3.\n\n          -  No evidence of viral resistance.\n\n          -  HIV RNA quantifiable by PCR.\n\n          -  Negativity for HBsAg, HBeAg, and anti-HBc.\n\n        NOTE:\n\n          -  Fifty percent of patients must have measurable p24 antigen levels (> 31 pg/ml).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active opportunistic infection requiring immediate treatment, such as tuberculosis,\n             cytomegalovirus, cerebral toxoplasmosis, and Pneumocystis carinii pneumonia.\n\n          -  Unable to maintain adequate oral intake.\n\n          -  Clinically significant vomiting and/or diarrhea.\n\n          -  Malignancy, visceral Kaposi's sarcoma, or lymphoma that will require systemic\n             chemotherapy within the next 12 months.\n\n          -  Unable to comply with protocol requirements, in the judgment of the investigator.\n\n          -  Any grade 3 or worse laboratory or clinical abnormality.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antineoplastic agents.\n\n          -  Concomitant or maintenance treatment with excluded experimental drugs and drugs with\n             known nephrotoxic or hepatotoxic potential.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy other than local skin radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Unexplained temperature >= 38.5 C (101.5 F) persisting for 14 days or more within a\n             30-day period.\n\n          -  Unexplained, chronic diarrhea persisting for 14 days or more within a 30-day period.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior treatment with an HIV proteinase inhibitor.\n\n          -  AZT within 30 days prior to study entry OR lasting more than 1 year.\n\n          -  Other antiretroviral therapy (besides AZT) within 30 days prior to study entry OR\n             lasting more than 14 days.\n\n          -  Acute therapy for an opportunistic infection within 14 days prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002111", 
            "org_study_id": "212A", 
            "secondary_id": "EV 14757"
        }, 
        "intervention": {
            "intervention_name": "Saquinavir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Saquinavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "AIDS-Related Complex", 
            "Saquinavir", 
            "HIV Protease Inhibitors"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "943055107"
                }, 
                "name": "Stanford Univ School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8633817", 
            "citation": "Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996 Jun 15;124(12):1039-50."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002111"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1995"
    }, 
    "geocoordinates": {
        "Stanford Univ School of Medicine": "37.429 -122.169"
    }
}